已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or ‘blips’ in HIV-1 subtype C

埃法维伦兹 病毒学 医学 苄腈 利比韦林 基因分型 逆转录酶抑制剂 人口 内科学 病毒载量 抗药性 逆转录酶 基因型 生物 人类免疫缺陷病毒(HIV) 聚合酶链反应 抗逆转录病毒疗法 遗传学 基因 环境卫生
作者
Ujjwal Neogi,Anders Sönnerborg
出处
期刊:AIDS [Lippincott Williams & Wilkins]
卷期号:28 (17): 2635-2636 被引量:3
标识
DOI:10.1097/qad.0000000000000463
摘要

The recent study from the Swiss HIV cohort described a limited clinical impact of minority K103N and Y181C mutants [1], which contradicts earlier studies showing that low-frequency HIV-1 drug-resistance mutations (DRMs), specifically non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations, were associated with increased risk of viral failure and decreased treatment efficacy [2–4]. However, in most of the studies, the minor mutations were detected with allele-specific PCR. In this study, sensitive high-throughput next-generation sequencing technology using Illumina MiSeq Bench-top sequencer with multiplexed amplicon sequencing was used, as described by us recently [5]. A total of 44 plasma samples obtained from patients followed at the Karolinska University Hospital were included. The patients were randomly chosen from a larger cohort of HIV-1 subtype B (HIV-1B) and subtype C (HIV-1C)-infected treatment-naïve patients at Karolinska, where all newly diagnosed patients are analysed for DRM by routine ViroSeq HIV-1 Genotyping System. No primary DRM was identified. Patients with less than years of follow-up (n = 4), treatment interruptions (n = 3), multiple treatment regimens (n = 3), lost to follow-up (n = 1), and use of ribavirin prior to therapy (n = 1) were excluded. Among the remaining 32 patients, 14 were initiated with NNRTI + two nucleoside reverse transcriptase inhibitors (NRTIs) [12 with efavirenz (EFV), one with rilpivirine (RPV) and one started with EFV and switched to RPV] and 18 with protease inhibitors + two NRTIs. The choice of the treatment was done on the discretion of the physician. Among the NNRTI-treated patients, seven each were infected with HIV-1B and HIV-1C. Seven HIV-1C and 11 HIV-1B patients, respectively, were given protease inhibitor. At baseline, primary minor NNRTI mutations (K103N, V108I, Y181C, and Y188C) were identified in three patients with HIV-1C and one with HIV-1B among those who initiated NNRTI therapy. One HIV-1C patient had the M230I mutation. Two HIV-1C patients also had M184V mutation. At follow-up, all four HIV-1C-infected patients had either low-level persistence viraemia or several viral ‘blips’ (viral load 20–1000 copies/ml). The HIV-1B-infected patient was suppressed successfully. However, four out of the nine NNRTI-treated patients without any minor mutation also had single viral ‘blips’ (two each in HIV-1B and HIV-1C). Thus, six out of the seven NNRTI-treated HIV-1C patients had at least one viral blip during a median duration of treatment of 51 months, whereas only two out of the seven HIV-1B-infected patients had viral ‘blips’ with no significant difference in the median duration of treatment (51 versus 44 months). In the protease inhibitor group, four out of the seven HIV-1C-infected patients had viral ‘blips’ or low-level viraemia, whereas four out of the 11 HIV-1B-infected patients had viral ‘blips’ (either single episode or twice). Altogether 10 out of the 14 HIV-1C patients had detectable viral RNA versus six out of the 18 HIV-1B patients during follow-up (P = 0.07). Our results are in line with the data from the Swiss cohort as none of our patients with minor mutations failed virologically (defined as viral load >1000 copies/ml) and the number of viral blips seemed not to be increased. However, the extent of viral ‘blips’ was comparatively high in HIV-1C patients. An earlier study has shown that virological and immunological responses are independent of HIV-1 subtypes, but viral rebound has been claimed to be more rapid in HIV-1C [6]. Therefore, larger and longer follow-up studies to understand the synergistic effects of viral ‘blips’ and minor primary DRMs should be prioritized, which could be feasible using cost-effective methods for detection of minor mutations such as the method we have recently developed [5]. Acknowledgements Funding: The study was partially funded by Swedish International Developing Agency, the Swedish Civil Contingencies Agency (SWE-2009–151) and the Swedish Research Council (521–2012–3476). Conflicts of interest There are no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
研友_ZAxj7n发布了新的文献求助10
1秒前
共享精神应助公孙世往采纳,获得10
2秒前
农村拓哉发布了新的文献求助10
2秒前
默梦完成签到,获得积分20
3秒前
Jemma发布了新的文献求助10
5秒前
善学以致用应助sopha采纳,获得10
5秒前
orangecake886完成签到,获得积分10
6秒前
6秒前
HelloKun完成签到,获得积分10
7秒前
8秒前
星空完成签到 ,获得积分10
9秒前
研友_VZG7GZ应助Jay采纳,获得10
10秒前
深情安青应助hyr采纳,获得10
11秒前
CipherSage应助Epiphany采纳,获得10
13秒前
农村拓哉完成签到,获得积分10
13秒前
小蘑菇应助科研通管家采纳,获得10
15秒前
SciGPT应助科研通管家采纳,获得10
15秒前
隐形曼青应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
qikkk应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
今后应助科研通管家采纳,获得10
15秒前
15秒前
77发布了新的文献求助40
16秒前
18秒前
19秒前
LQX2141发布了新的文献求助10
20秒前
20秒前
22秒前
Owen应助学术悍匪采纳,获得10
22秒前
俭朴的跳跳糖完成签到 ,获得积分10
22秒前
Epiphany发布了新的文献求助10
23秒前
mimimi完成签到,获得积分10
23秒前
keken发布了新的文献求助10
25秒前
Wang完成签到 ,获得积分10
27秒前
hyr发布了新的文献求助10
28秒前
28秒前
Epiphany完成签到,获得积分10
29秒前
量子星尘发布了新的文献求助10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976455
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203728
捐赠科研通 3257156
什么是DOI,文献DOI怎么找? 1798618
邀请新用户注册赠送积分活动 877819
科研通“疑难数据库(出版商)”最低求助积分说明 806523